key: cord-1032326-gb8kjxdd authors: Park, Jung E.; Kwon, Kyum‐Yil title: Coronavirus disease 2019‐associated worsening and improvement of ataxia and gait in a patient with multiple system atrophy date: 2021-05-18 journal: Geriatr Gerontol Int DOI: 10.1111/ggi.14184 sha: 84f899c8df90fceef1f70f93e3341790b0034919 doc_id: 1032326 cord_uid: gb8kjxdd nan over the past year. On neurological examination, mild saccadic hypermetria and dysarthria were noted. A mild postural tremor was seen in bilateral upper extremities. Rigidity and bradykinesia were present in all limbs, with the latter slightly more prominent in the right upper and lower extremities. Limb ataxia was present on performing finger-to-nose and heel-to-shin, of which the latter was found to be more prominent. Although the patient was found to have a moderate degree of postural instability, he was able to ambulate independently. A review of systems was positive for urinary incontinence and dizziness, and his orthostatic vital signs were later confirmed to meet the criteria for orthostatic hypotension. His past medical history was positive for hypertension, diabetes mellitus and atrial fibrillation. Axial T2-weighted images of brain magnetic resonance imaging showed the hot cross bun sign and pontocerebellar atrophy (Fig. 1a,b) . Dopamine transporter imaging showed a dopaminergic deficit most prominent in the left putamen (Fig. 1c) . According to the current diagnostic criteria for MSA, we concluded that the patient had probable MSA of the cerebellar type. 2 One month later, the patient was admitted to Soon-chunhyangUniversity Seoul Hospital in Seoul, South Korea for rapid worsening of his neurological symptoms, including slurred speech, clumsiness and gait difficulty, developing over the past week. He was initially started on levodopa/benserazide 100/25 mg/ day, for possible symptomatic benefit. The patient was admitted for further observation and on the day of admission, developed a fever of 38.1 C with mild respiratory symptoms, including dyspnea, cough and sputum. Real-time reverse transcription polymerase chain reaction test for the qualitative detection of nucleic acid from SARS-CoV-2 was carried out on the patient's nasopharyngeal and oropharyngeal swab specimens, and were found to be positive. High-resolution computed tomography scan of the chest showed multifocal patchy lesions in bilateral lungs (Fig. 1d) , compatible with findings of COVID-19. The COVID-19 infection itself was only mild, both clinically and radiologically. The patient was briefly put on 3 L of oxygen (through nasal prong), with an oxygen saturation level of 9697%. He was given daily intravenous remdesivir 100 mg/day for 5 days and dexamethasone 6 mg/ day for 10 days. Although the patient's respiratory symptoms gradually improved over the course of a month, his neurological symptoms, including dysarthria, limb ataxia and gait ataxia with postural instability, were found to worsen in the first 2 weeks. Features of parkinsonism including rigidity and bradykinesia were found to be relatively unchanged. He could neither stand nor even walk with assistance during this period while he received treatment for COVID-19. However, the patient's neurological status was found to gradually improve to baseline, and he was ultimately discharged 6 weeks after admission. All procedures performed were carried out in accordance with national law and the Helsinki Declaration of 1964 (in its present revised form). Informed consent was obtained from the patient. To the best of our knowledge, this is the first documented report of a patient with MSA infected by SARS-CoV-2. Initially, abrupt worsening of his neurological symptoms with COVID-19 were concerning, as a recent report suggested that COVID-19 in patients with PD might result in poor prognosis, such as rapid clinical decline leading to sudden death. 3 A report of a patient with PD with only mild COVID-19 related abnormalities on chest computed tomography was found to result in a fatal course. However, we found the present patient with MSA to experience only mild respiratory symptoms, and undergo only transient worsening and return to baseline neurologically. Therefore, based on the present case, we presume that COVID-19 itself does not appear to lead to long-lasting worsening motor symptoms in MSA. Furthermore, the present case suggests that the prognosis of parkinsonian patients infected with COVID-19 might vary. It remains unclear whether such a difference of clinical outcomes in PD and MSA is due to primary brain pathology or secondary pathology as a result of COVID-19 infection. Therefore, more reports are required to address this issue. The current case suggests that clinicians should consider the possibility of SARS-CoV-2 infection when patients with parkinsonism present with acute worsening of their motor symptoms. To date, little is known about the precise mechanism of how COVID-19 could induce such worsening. One possibility is that infection could accelerate the pathology of alpha-synucleinopathies. 4 However, the present patient only showed transient worsening of neurological symptoms, giving rise to the possibility of factors such as psychological stress or reduced physical activity as a cause. 5 The present case might provide clinicians with an initial glimpse into the association between COVID-19 and multiple system atrophy. Future observations regarding worsening of neurological symptoms and signs in PD and MSA are required in this era of COVID-19 pandemic. Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study Second consensus statement on the diagnosis of multiple system atrophy Rapid worsening in Parkinson's disease may hide COVID-19 infection Can infections trigger alpha-synucleinopathies? The impact of the COVID-19 pandemic on Parkinson's disease: hidden sorrows and emerging opportunities How to cite this article: Park JE Coronavirus disease 2019-associated worsening and improvement of ataxia and gait in a patient with multiple system atrophy This work was supported by the Soonchunhyang University Research Fund (No. 20201239). The authors declare no conflict of interest.